Clinical CDK2 Inhibitors: Trends to Selectivity and Efficacy-Reference-Cited by-同舟云学术

Clinical CDK2 Inhibitors: Trends to Selectivity and Efficacy

Published:2023-05 Issue:2 Volume:18 Page:102-107
ISSN:1574-8928
Container-title:Recent Patents on Anti-Cancer Drug Discovery
language:en
Short-container-title:PRA

Author:

Novikov Fedor N.¹²,Rusina Polina V.³¹,Lisov Alexey A.³¹,Denisova Alexandra A.⁴,Gandalipov Erik R.⁵,Shtil Alexander A.³⁶

Affiliation:

1. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 47 Leninsky Avenue, 119991, Moscow, Russian Federation

2. National Research University `Higher School of Economics\', 20 Myasnitskaya Street, 101000, Moscow, Russian Federation

3. Department of Chemistry, Lomonosov Moscow State University, 1/3 Leninskie Gory, 119991, Moscow, Russian Federation

4. Faculty of Bioengineering and Bioinformatics, Moscow State University, 1-73 Leninskie Gory, 119234, Moscow, Russian Federation

5. International Institute of Solution Chemistry and Advanced Materials Technologies, ITMO University, 9 Lomonosov Street, 191002, Saint-Petersburg, Russian Federation

6. Blokhin National Medical Research Center of Oncology, 24 Kashirskoye shosse, 115478, Moscow, Russian Federation

Abstract

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology (medical),Cancer Research,Drug Discovery,Oncology,General Medicine

Reference28 articles.

1. Tadesse S.; Anshabo A.T.; Portman N.; Targeting CDK2 in cancer: Challenges and opportunities for therapy. Drug Discov Today 2020,25(2),406-413

2. Echalier A.; Hole A.J.; Lolli G.; Endicott J.A.; Noble M.E.M.; An inhibitor’s-eye view of the ATP-binding site of CDKs in different regulatory states. ACS Chem Biol 2014,9(6),1251-1256

3. Jorda R; Hendrychová D; Voller J; Řezníčková E; Gucký T; Kryštof V; How selective are pharmacological inhibitors of cell-cycle-regulating cyclindependent kinases? J Med Chem 2018,61(20),9105-9120

4. Whittaker S.R.; Mallinger A.; Workman P.; Clarke P.A.; Inhibitors of cyclin-dependent kinases as cancer therapeutics. Pharmacol Ther 2017,173,83-105

5. Zhang M.; Zhang L.; Hei R.; CDK inhibitors in cancer therapy, an overview of recent development. Am J Cancer Res 2021,11(5),1913-1935

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Development of CDK2 Inhibitors as Anticancer Drugs: An Update (2015–2023);Pharmaceutical Fronts;2024-09-03

2. Imidazole-4-N-acetamide Derivatives as a Novel Scaffold for Selective Targeting of Cyclin Dependent Kinases;Cancers;2023-07-25